Dale Joachim

Dale Joachim

Auto-generated profile, based on publicly available information

Dale Joachim

Speech Science, Sonde Health Inc, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ELErik Larsen
Erik Larsen
XSXinyu Song
Xinyu Song
DJDale Joachim
Dale Joachim
PCPeter Ch'EN
Peter Ch'EN
SGSamuel Green
Samuel Green
SJSunit Jariwala
Sunit Jariwala
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Asthma exacerbations are a significant issue due to poor perception and failure of traditional monitoring techniques to capture real-time changes in respiratory function. There is a need for strategies to enhance recognition and facilitate timely intervention. Objective: To evaluate the efficacy of a respiratory-responsive vocal biomarker (RRVB), accessible via smartphone application, as a convenient real-time tool for monitoring asthma exacerbations and respiratory states. Methods: In this three-month prospective cohort study, 84 asthma patients recorded daily 6-second vocal samples, generating RRVB scores. The RRVB's ability to predict asthma exacerbations and respiratory states (normal function, mild events, exacerbations) was assessed using risk ratios (RR) and confidence intervals (CIs). Respiratory states were defined using peak expiratory flow (PEF) and self-reported wellbeing, with exacerbations identified by a decline in both PEF and wellbeing, and mild events by a decline in one measure. Results: RRVB scores significantly predicted asthma exacerbations, with a risk ratio of 2.15 (95% CI: 1.62-2.85, p < .001), and 3.57 (95% CI: 2.70-4.73, p < .001) using normalized scores adjusted for individual characteristics. However, time-averaged RRVB scores did not significantly correlate with asthma control as measured by the Asthma Control Test (ACT), with a risk ratio of 1.17 (95% CI: 0.96-1.44, p = .12). A total of 58% of participants remained engaged throughout the study, reporting high satisfaction with the tool's usability and perceived benefits for asthma management. Conclusions: This study demonstrates potential enhancements in asthma management through more accessible and continuous monitoring of respiratory function offered by the RRVB tool, which was shown to provide an effective, real-time, and user-friendly approach for detecting potential exacerbations. Clinical Trial: clinicaltrials.gov: NCT05850390

12 November 2024 in JMIR Preprints
Verified
Preprint
Open access
ELErik Larsen
Erik Larsen
XSXinyu Song
Xinyu Song
DJDale Joachim
Dale Joachim
PCPeter Y Ch'EN
Peter Y Ch'EN
SGSamuel M Green
Samuel M Green
SJSunit Jariwala
Sunit Jariwala
BACKGROUND Asthma exacerbations remain a major challenge in asthma management, often due to delayed recognition and limitations of conventional monitoring tools such as peak flow meters and symptom questionnaires. These tools are typically effort dependent or retrospective, making them less suited for continuous, real-time monitoring. A novel, smartphone-based respiratory-responsive vocal biomarker (RRVB) may offer an accessible and noninvasive approach for dynamic assessment of respiratory health. This RRVB has previously demonstrated generalizable performance in cross-sectional cohorts across multiple respiratory conditions, including asthma, chronic obstructive pulmonary disease, and COVID-19, in populations spanning India and the United States. This study extended this work by evaluating the real-world, longitudinal performance of the same RRVB tool for daily asthma exacerbation monitoring via smartphones in home settings. OBJECTIVE This study aimed to evaluate the efficacy of the RRVB as a convenient real-time tool for monitoring asthma exacerbations and respiratory states in a real-world, longitudinal setting. METHODS In this prospective cohort study, 84 adult patients with asthma were enrolled from an academic medical center and followed for 90 days. Participants submitted daily 6-second voice samples and conducted peak expiratory flow measurements and surveys, including symptom reports and asthma control assessments. RRVB scores were generated in real time on the app. Asthma states (normal function, mild event, and exacerbation) were defined based on both peak expiratory flow and self-reported well-being. Risk ratios were calculated to assess the predictive validity of RRVB scores for identifying exacerbation events. Engagement was measured via frequency of completed sessions, and participant experience was evaluated through exit surveys. RESULTS RRVB scores significantly stratified asthma states. The risk of experiencing an exacerbation was 2.15 times higher (95% CI 1.62-2.85; P<.001) with elevated RRVB scores and 3.57 times higher (95% CI 2.70-4.73; P<.001) using normalized scores adjusted for individual characteristics. RRVB scores did not significantly correlate with the Asthma Control Test (risk ratio=1.17, 95% CI 0.96-1.44; P=.12), highlighting its role as a momentary signal rather than a proxy for longitudinal control. Engagement was moderate or higher (≥26 total app sessions) in 58% (49/84) of participants. Among survey respondents, 93% (43/46) found the app easy to use, 89% (41/46) reported a positive overall experience, and 87% (40/46) indicated that they would use a similar tool in the future. Fewer participants (32/46, 70%) reported understanding the RRVB scores, suggesting a need for improved score interpretability and user guidance in future implementations. CONCLUSIONS The RRVB tool demonstrated effective real-time detection of asthma exacerbations and dynamic respiratory states, supporting its potential as a noninvasive, user-friendly, and physiologically grounded digital biomarker for asthma monitoring. These findings provide foundational evidence for broader deployment and integration of voice-based tools to support proactive, real-world asthma management.

1 January 2026 in Journal of Physical Activity and Health
Verified
Journal Article
Closed access
PDF file
LMLeapetswe Malete
Leapetswe Malete
CRChelsi Ricketts
Chelsi Ricketts
VNVida Korleki Nyawornota
Vida Korleki Nyawornota
EHEmily Hayashi
Emily Hayashi
ROReginald Tetteh-Ahumah Ocansey
Reginald Tetteh-Ahumah Ocansey
NMNoel Mann
Noel Mann
Background : Physical inactivity and mental distress were prevalent across African populations during COVID-19. However, limited research has explored the role of sedentary time in shaping mental health outcomes during the pandemic. In this study, sedentary time during COVID-19 and its moderating role in the relationship between COVID-19 symptom burden and mental health outcomes were examined in Botswana, Ghana, Nigeria, and Tanzania. Methods : Cross-sectional data (April 2020 to November 2022) from 3125 adults (male = 52.3%, M age = 27.05, SD = 8.91) were analyzed. Participants completed self-report measures of COVID-19 symptoms (eg, persistent cough and unusual fatigue), physical activity and sedentary time (International Physical Activity Questionnaire-Short Form), as well as anxiety (Generalized Anxiety Disorder 7) and depressive symptoms (Patient Health Questionnaire). Results : Median sedentary time per day was lower in Nigeria (median = 120, interquartile range = 150) and Tanzania (median = 120, interquartile range = 180) than in Botswana and Ghana (median = 180, interquartile range = 180). Overall, sedentary time moderated the positive relationship between COVID-19 symptom burden and depressive symptoms ( B = 0.60, P = .012), with stronger associations at higher sitting time (simple slope: B = 2.27, P < .001). At the country level, this moderating effect was observed only in Ghana ( B = 1.38, P < .001; simple slope: B = 2.40, P < .001). Conclusions : These findings highlight cross-country variation in sedentary time during the pandemic and suggest that greater sedentary time exacerbated the relationship between COVID-19 symptom burden and depressive symptoms, particularly in Ghana. Context-specific factors and differing pandemic responses may help explain these country-level differences.